×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OVID – ovid therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OVID
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/24
09:36 am
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Low
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
3/12
08:07 pm
ovid
Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
High
Report
Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
3/12
09:11 am
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "outperform" rating re-affirmed by analysts at Wedbush.
Medium
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "outperform" rating re-affirmed by analysts at Wedbush.
3/11
08:00 am
ovid
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
3/3
08:00 am
ovid
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
High
Report
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
2/27
08:00 am
ovid
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Low
Report
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
2/5
08:00 am
ovid
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Medium
Report
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/29
01:21 pm
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $4.00 price target on the stock.
Low
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $4.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/11
09:09 am
ovid
Form 10-K Ovid Therapeutics Inc. For: Dec 31
Low
Report
Form 10-K Ovid Therapeutics Inc. For: Dec 31
3/11
08:51 am
ovid
Form 8-K Ovid Therapeutics Inc. For: Mar 10
Low
Report
Form 8-K Ovid Therapeutics Inc. For: Mar 10
3/5
04:08 pm
ovid
Form 8-K Ovid Therapeutics Inc. For: Mar 01
Medium
Report
Form 8-K Ovid Therapeutics Inc. For: Mar 01
3/4
04:44 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Mar 03 Filed by: PAPADOPOULOS STELIOS
Medium
Report
Form 4 Ovid Therapeutics Inc. For: Mar 03 Filed by: PAPADOPOULOS STELIOS
3/4
04:43 pm
ovid
Form 3 Ovid Therapeutics Inc. For: Mar 01 Filed by: PAPADOPOULOS STELIOS
Medium
Report
Form 3 Ovid Therapeutics Inc. For: Mar 01 Filed by: PAPADOPOULOS STELIOS
2/28
04:15 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Feb 26 Filed by: ALEXANDER MARGARET A.
High
Report
Form 4 Ovid Therapeutics Inc. For: Feb 26 Filed by: ALEXANDER MARGARET A.
2/28
04:15 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Feb 26 Filed by: Rona Jeffrey A
High
Report
Form 4 Ovid Therapeutics Inc. For: Feb 26 Filed by: Rona Jeffrey A
2/24
07:55 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Feb 20 Filed by: ALEXANDER MARGARET A.
Low
Report
Form 4 Ovid Therapeutics Inc. For: Feb 20 Filed by: ALEXANDER MARGARET A.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/24
Form 8-K Ovid Therapeutics Inc. For: Sep 23
25.5%
6/18 Form 8-K Ovid Therapeutics Inc. For: Jun 18 14.2%
11/29 RBC bullish on OVID's 2020 catalysts [Seeking Alpha] 10.4%
9/23 Form 8-K Ovid Therapeutics Inc. For: Sep 23 10.3%
8/17 Ovid Therapeutics Inc (NASDAQ: OVID) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 9.8%
7/1 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at Cowen Inc. 9.6%
7/18 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.4%
10/10 Form 4 Ovid Therapeutics Inc. For: Oct 08 Filed by: LEVIN JEREMY M 7.5%
11/15 Form 4 Ovid Therapeutics Inc. For: Nov 13 Filed by: Bernstein Karen 6.6%
12/20 Form 4 Ovid Therapeutics Inc. For: Dec 18 Filed by: Perone Thomas Michael 6.0%
6/18 Form 8-K Ovid Therapeutics Inc. For: Jun 18 14.2%
11/29 RBC bullish on OVID's 2020 catalysts [Seeking Alpha] 10.4%
9/23 Form 8-K Ovid Therapeutics Inc. For: Sep 23 10.3%
8/17 Ovid Therapeutics Inc (NASDAQ: OVID) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 9.8%
7/1 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at Cowen Inc. 9.6%
7/18 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.4%
10/10 Form 4 Ovid Therapeutics Inc. For: Oct 08 Filed by: LEVIN JEREMY M 7.5%
11/15 Form 4 Ovid Therapeutics Inc. For: Nov 13 Filed by: Bernstein Karen 6.6%
12/20 Form 4 Ovid Therapeutics Inc. For: Dec 18 Filed by: Perone Thomas Michael 6.0%
TOP News Decliners
3/12
Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-28.1%
10/3 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock -26.8%
3/11 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 -18.8%
3/6 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock. -13.4%
5/7 Q1/2019 3/31/2019 EPS -0.460 ZacksConsensus N/A ActVsEst N/A - N/A -11.3%
6/27 Form 8-K Ovid Therapeutics Inc. For: Jun 27 -7.5%
9/26 Ovid Therapeutics Inc (NASDAQ: OVID) was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -6.9%
2/14 Form SC 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M -6.8%
11/4 Form 4 Ovid Therapeutics Inc. For: Nov 01 Filed by: Daly Timothy -5.9%
8/22 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
10/3 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock -26.8%
3/11 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 -18.8%
3/6 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock. -13.4%
5/7 Q1/2019 3/31/2019 EPS -0.460 ZacksConsensus N/A ActVsEst N/A - N/A -11.3%
6/27 Form 8-K Ovid Therapeutics Inc. For: Jun 27 -7.5%
9/26 Ovid Therapeutics Inc (NASDAQ: OVID) was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -6.9%
2/14 Form SC 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M -6.8%
11/4 Form 4 Ovid Therapeutics Inc. For: Nov 01 Filed by: Daly Timothy -5.9%
8/22 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: